New AI system could revolutionize the diagnosis of valvular heart disease

AI (artificial intelligence) may sound like a cold robotic system, but Osaka Metropolitan University scientists have shown that it can deliver heartwarming-;or, more to the point, "heart-warning"-;support. They unveiled an innovative use of AI that classifies cardiac functions and pinpoints valvular heart disease with unprecedented accuracy, demonstrating continued progress in merging the fields of medicine and technology to advance patient care. The results will be published in The Lancet Digital Health.

Valvular heart disease, one cause of heart failure, is often diagnosed using echocardiography. This technique, however, requires specialized skills, so there is a corresponding shortage of qualified technicians. Meanwhile, chest radiography is one of the most common tests to identify diseases, primarily of the lungs. Even though the heart is also visible in chest radiographs, little was known heretofore about the ability of chest radiographs to detect cardiac function or disease. Chest radiographs, or chest X-Rays, are performed in many hospitals and very little time is required to conduct them, making them highly accessible and reproducible. Accordingly, the research team led by Dr. Daiju Ueda, from the Department of Diagnostic and Interventional Radiology at the Graduate School of Medicine of Osaka Metropolitan University, reckoned that if cardiac function and disease could be determined from chest radiographs, this test could serve as a supplement to echocardiography.

Dr. Ueda's team successfully developed a model that utilizes AI to accurately classify cardiac functions and valvular heart diseases from chest radiographs. Since AI trained on a single dataset faces potential bias, leading to low accuracy, the team aimed for multi-institutional data. Accordingly, a total of 22,551 chest radiographs associated with 22,551 echocardiograms were collected from 16,946 patients at four facilities between 2013 and 2021. With the chest radiographs set as input data and the echocardiograms set as output data, the AI model was trained to learn features connecting both datasets.

The AI model was able to categorize precisely six selected types of valvular heart disease, with the Area Under the Curve, or AUC, ranging from 0.83 to 0.92. (AUC is a rating index that indicates the capability of an AI model and uses a value range from 0 to 1, with the closer to 1, the better.) The AUC was 0.92 at a 40% cut-off for detecting left ventricular ejection fraction-;an important measure for monitoring cardiac function.

It took us a very long time to get to these results, but I believe this is significant research. In addition to improving the efficiency of doctors' diagnoses, the system might also be used in areas where there are no specialists, in night-time emergencies, and for patients who have difficulty undergoing echocardiography."

Dr. Daiju Ueda, Department of Diagnostic and Interventional Radiology, Graduate School of Medicine of Osaka Metropolitan University

Source:
Journal reference:

Ueda, D., et al. (2023) Artificial intelligence-based model to classify cardiac functions from chest radiographs: a multi-institutional, retrospective model development and validation study. The Lancet Digital Health. doi.org/10.1016/S2589-7500(23)00107-3.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events